ASCO Annual Meeting

Combination of Chemotherapy and Radiation Therapy Lengthens Lives of Patients With Anaplastic Oligodendroglial Tumors

ASCO Annual Meeting
June 3, 2012

A recent study by the European Organisation for Research and Treatment of Cancer (EORTC) shows that chemotherapy after radiation therapy slowed the growth of anaplastic oligodendroglial tumors (a type of brain tumor). It also lengthened the lives of patients with this type of tumor, especially for those whose tumor was missing specific genetic material in chromosomes 1 and 19 (called 1p/19q co-deletions). Currently, most patients with this disease receive either chemotherapy or radiation therapy, but not both.

Targeted Therapy Combination for Lymphoma Is More Effective Than Standard Chemotherapy

ASCO Annual Meeting
June 3, 2012

A long-term study shows that a combination of bendamustine (Treanda) and rituximab (Rituxan) keeps two uncommon types of non-Hodgkin lymphoma (NHL), indolent (slow-growing) lymphoma and mantle cell lymphoma, from worsening longer than standard chemotherapy. Bendamustine and rituximab are drugs called targeted therapies. Targeted therapy is a treatment that targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.

Lower-Income Patients Less Likely to Participate in Clinical Trials

ASCO Annual Meeting
June 3, 2012

A large national survey of people with cancer showed that a patient's income strongly predicts whether he or she will participate in a clinical trial. A clinical trial is a research study involving people. A clinical trial may focus on new treatments, new methods to prevent cancer, and ways to manage the symptoms and side effects of cancer and cancer treatment.

Promising New Immunotherapy for Melanoma, Kidney Cancer, and Non-Small Cell Lung Cancer

ASCO Annual Meeting
June 2, 2012

A new immunotherapy (called BMS-936558) helped shrink melanoma, kidney cancer, and non-small cell lung cancer (NSCLC) in a recent early study. Immunotherapy is designed to boost the body's natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to bolster, target, or restore immune system function.

Preliminary Study Shows that the Lung Cancer Drug, Crizotinib, Is Effective for Three Childhood Cancers

ASCO Annual Meeting
May 16, 2012

In an early study with the targeted therapy drug crizotinib (Xalkori), researchers found that it stopped the growth of neuroblastoma, anaplastic large cell lymphoma (ALCL), and inflammatory myofibroblastic tumors (IMT), and in some instances, removed all signs of the cancer.

Pages

Subscribe to RSS - ASCO Annual Meeting